After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

This time last year, Candel Therapeutics was burning at both ends. Now, despite tough decisions, the cancer immunotherapy company is celebrating a major win.

For a clinical-stage biotech, navigating the treacherous market of the last few years is a testament to perseverance and resilience, as well as a belief in the fundamental science behind that work. Candel emerged from that harrowing landscape — through layoffs and other sacrifices — with late-stage clinical data that holds promise in the tricky area of prostate cancer, shedding light on a new approach in immuno-oncology.